# Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC

Source: https://onco.cc/trials/nct05557838/  
OnCo record `nct05557838` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab, Tremelimumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.

## Summary

Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC is a phase 3 interventional study registered as NCT05557838 by AstraZeneca, with 214 participants enrolled, started 2023-02-15 and due to reach its primary completion in 2026-09-30. Interventions recorded: Durvalumab, Tremelimumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05557838
- Phase: 3
- Setting: An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma
- Sponsor: AstraZeneca
- Enrolled: 214

## Sources

- ClinicalTrials.gov NCT05557838: https://clinicaltrials.gov/study/NCT05557838

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05557838.json